Related Experiment Video

Updated: Aug 6, 2026

Morphometric Analyses of Retinal Sections
14:33

Morphometric Analyses of Retinal Sections

Published on: February 19, 2012

Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma

L A Wheeler1, D W Gil, E WoldeMussie

  • 1Department of Biological Sciences, Allergan, Inc., Irvine, CA 92612, USA.

Survey of Ophthalmology
|May 30, 2001
PubMed

Insights

Brimonidine, an alpha-2 agonist, shows neuroprotective effects by enhancing retinal ganglion cell (RGC) survival in glaucoma models. Further clinical trials are underway to confirm its therapeutic potential in humans.

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma is characterized by progressive loss of retinal ganglion cells (RGCs) over many years.
  • Neuroprotective drugs aim to enhance RGC survival against chronic stress and injury.

Purpose of the Study:

  • To evaluate brimonidine, an alpha-2 agonist, as a potential neuroprotective agent for glaucoma.
  • To assess if brimonidine meets established criteria for therapeutic utility in human glaucoma.

Main Methods:

  • Localized alpha-2A receptors in the inner rat retina using immunohistochemistry.
  • Assessed brimonidine's neuroprotective effect in rat models of optic nerve injury and chronic hypertension.
  • Evaluated RGC loss reduction and timing of drug administration relative to injury.

Main Results:

  • Brimonidine demonstrated neuroprotection in rat models, significantly reducing RGC loss.
  • Neuroprotective effects were observed even when brimonidine was administered hours before injury, suggesting long-term resistance enhancement.
  • A clinical trial in non-arteritic ischemic optic neuropathy patients has been initiated.

Conclusions:

  • Brimonidine fulfills key criteria for a glaucoma neuroprotective drug, including retinal target presence and demonstrated efficacy in animal models.
  • The drug's ability to enhance RGC resistance to stress supports its therapeutic potential.
  • Clinical evaluation is crucial to confirm brimonidine's efficacy in human glaucoma patients.

More Related Videos

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...